-transparent.png){kind=logo}
The bronchodilating effect and other related pharmacological properties of SN-408 were studied in comparison with those of isoproterenol, salbutamol and procaterol. SN-408 caused concentration-dependent relaxation of isolated guinea pig trachea via the beta 2-adrenoceptor. The order of relaxation potency was: procaterol greater than SN-408 greater than or equal to isoproterenol greater than salbutamol, but the duration of the action of SN-408 was far longer than those of other beta-agonists. Positive chronotropic and inotropic actions of SN-408 in isolated guinea pig right atria and left atria were less potent than those of other beta-agonists. In isolated guinea pig lung tissues, SN-408 increased cyclic AMP contents. Also in vivo, SN-408 showed dose-dependent bronchodilating action by i.v. administration in anesthetized guinea pigs and by inhalation in conscious guinea pigs. Bronchodilating actions of SN-408 were less potent than those of procaterol and isoproterenol, but the duration of action of SN-408 was far longer than those of other beta-agonists. SN-408 showed no evidence of the development of tolerance to the bronchodilating action. SN-408 caused small tachycardia in guinea pigs by i.v. and inhalation. SN-408 given i.v. suppressed vascular permeability in mice. These results indicate that SN-408 is a long-acting and selective beta 2-stimulant bronchodilator.
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
November 1991,
British journal of pharmacology,
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
December 1993,
The Annals of pharmacotherapy,
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
June 2010,
Core evidence,
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
January 1990,
Lung,
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
January 2013,
The Journal of pharmacology and experimental therapeutics,
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
August 1994,
Biological & pharmaceutical bulletin,
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
October 1995,
European journal of pharmacology,
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
December 1992,
European journal of pharmacology,
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
April 1998,
The Journal of the American Osteopathic Association,
M Nishimura, and
M Okiyama, and
H Fujiwara, and
M Kudo, and
M Simizu, and
M Maeda, and
M Yamada, and
Y Toshimitsu
January 2002,
Rheumatology (Oxford, England),
